Eli Lilly Co Awarded $525M for doses of the combination therapeutic
Eli Lilly Co., Indianapolis, Indiana, was awarded a $525,000,000 modification (P00006) to contract W911QY-21-D-0012 for doses of the combination therapeutic. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of Jan. 31, 2022. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W911QY-21-D-0012).
Eli Lilly is a leading pharmaceutical company that develops diabetes, oncology, immunology, and neuroscience medicines. Its top-selling drugs include Trulicity (treatment of type 2 diabetes and reducing the risk of adverse cardiovascular events in patients with type 2 diabetes and cardiovascular risk factors); Humalog (an injectable human insulin analog); Alimta (treatment for various cancers); Taltz (treatment for moderated-to-severe plaque psoriasis); Humulin (injectable human insulin); and Jardiance (treatment for type 2 diabetes and reducing the risk of cardiovascular death with patients with type 2 diabetes and heart diseases) among others. The company generates most of its revenue in the US. (www.dnb.com)